Ablative Therapy for Barrett's Esophagus

February 16, 2011

The author of a study that compared the cost utility of ablation with that of endoscopic surveillance strategies explains his findings.

In this video from the American Gastroenterological Association, John M. Inadomi, MD, discusses the article "Ablative Therapy for Barretts Esophagus: A Cost-Utility Analysis.” The authors of the article compared the cost utility of ablation with that of endoscopic surveillance strategies. They concluded that endoscopic ablation “could be the preferred strategy for managing patients with Barrett's esophagus with high-grade dysplasia. Ablation might also be preferred in subjects with low-grade dysplasia or no dysplasia, but the cost effectiveness depends on the long-term effectiveness of ablation and whether surveillance endoscopy can be discontinued after successful ablation.